Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Amunix to receive $40 million in upfront payment and may receive up to $1.5 billion in development and sales milestones
- Roche to utilize XTEN, Amunix?s clinically validated therapeutic half-life extension technology, to discover and develop novel therapeutics